Bellicum Pharmaceuticals, Inc.
BLCM · NASDAQ
9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Revenue | $1,000 | $0 | $8 | $500 |
| % Growth | – | -100% | -98.4% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $1,000 | $0 | $8 | $500 |
| % Margin | 100% | – | 100% | 100% |
| R&D Expenses | $263 | $4,808 | $7,216 | $6,339 |
| G&A Expenses | $1,511 | $2,259 | $1,437 | $1,501 |
| SG&A Expenses | $1,511 | $2,259 | $1,437 | $1,501 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $3 | $0 | $0 | $0 |
| Operating Expenses | $1,774 | $7,067 | $8,653 | $7,840 |
| Operating Income | -$1 | -$7,067 | -$8,645 | -$7,340 |
| % Margin | -0.1% | – | -108,062.5% | -1,468% |
| Other Income/Exp. Net | $10 | -$285 | $579 | $1,145 |
| Pre-Tax Income | -$763 | -$7,352 | -$8,066 | -$6,195 |
| Tax Expense | $0 | $0 | -$579 | $0 |
| Net Income | -$763 | -$7,352 | -$7,487 | -$6,195 |
| % Margin | -76.3% | – | -93,587.5% | -1,239% |
| EPS | -0.025 | -0.24 | -0.24 | -0.2 |
| % Growth | 89.7% | 0% | -20% | – |
| EPS Diluted | -0.025 | -0.24 | -0.24 | -0.2 |
| Weighted Avg Shares Out | 30,905 | 30,835 | 30,834 | 30,830 |
| Weighted Avg Shares Out Dil | 30,905 | 30,835 | 30,834 | 30,830 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2 | $3 | $5 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $2 | $2 | -$571 | -$2,000 |
| EBITDA | -$1 | -$7,065 | -$8,645 | -$7,349 |
| % Margin | -0.1% | – | -108,062.5% | -1,469.8% |